In this episode, Prof. Friedemann Paul from Charité – Universitätsmedizin Berlin, Germany, explains how the European CLAIMS project aims to improve multiple sclerosis care through AI-assisted decision support. CLAIMS brings together MRI, OCT, blood biomarkers such as neurofilament light chain, clinical data and patient-reported outcomes to support more precise predictions of MS progression.

This episode is supported by the European Charcot Foundation.

We talk about precision medicine, RAW and PIRA progression, trust in AI, clinical validation, access, reimbursement and what it takes to bring such a tool into everyday neurological care. A key message of the episode: AI should support neurologists and shared decision making — not replace them.

You can find the written interview here: https://ms-perspektive.de/172-claims/

Topics covered

• What CLAIMS aims to achieve for people with MS
• Why precision medicine matters in multiple sclerosis
• How MRI, OCT, biomarkers and patient-reported outcomes can be integrated
• RAW and PIRA progression explained
• Why AI will not replace neurologists
• How trust, transparency and data quality influence AI-supported care
• Validation, approval, reimbursement and implementation in daily practice
• How people with MS and clinicians can stay updated or get involved

Resources mentioned

• CLAIMS project: https://www.claims.ms/
• PROCLAIM study: https://www.claims.ms/proclaim/
• European Charcot Foundation – CLAIMS initiative: https://www.charcot-ms.org/initiatives/claims-clinical-impact-through-ai-assisted-ms-care
• RECLAIM study protocol:
  https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1557947/full
• PROCLAIM study:
  https://clinicaltrials.gov/study/NCT07032246
• icometrix / icobrain ms:
  https://www.icometrix.com/multiple-sclerosis

What message would you like to leave with our listeners today?

Prof. Friedemann Paul: There is hope for better management of the disease.

We desperately need this because more and more people are being diagnosed with multiple sclerosis.

And we need more and better data.

If you have time and resources, please consider contributing to research. This could be an observational study, a therapeutic trial, a study on lifestyle or another local research project.

It is really important.

We can only improve outcomes in multiple sclerosis if we do more research.

---

See you soon and try to make the best out of your life,
Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.